Skip to main content
Top
Published in: Journal of Ovarian Research 1/2019

Open Access 01-12-2019 | Ovarian Cancer | Review

Proactive use of PROMs in ovarian cancer survivors: a systematic review

Authors: Anette Stolberg Kargo, Angela Coulter, Pernille Tine Jensen, Karina Dahl Steffensen

Published in: Journal of Ovarian Research | Issue 1/2019

Login to get access

Abstract

Introduction

The use of patient reported outcome measures (PROMs) has increased during the past decade, and the focus on how to use them has resulted in a more proactive application. Studies have shown that proactive use of PROMs during treatment improves patient-clinician communication, leads to better symptom management and may prolong survival among advanced cancer patients. Ovarian cancer is a serious disease in which the majority of patients experience recurrence during the follow-up period and suffer from a number of severe symptoms from underlying disease. This systematic review was conducted to assess the evidence on the proactive use of PROMs as a dialogue tool during follow-up of ovarian cancer patients.

Results

The following databases were searched for relevant literature; PubMed, EMBASE, CINAHL, and the Cochrane Library. The search was conducted in April 2019 without any filters or limits. A total of 643 publications were identified, and 48 studies were found to be potentially eligible. Of the 48 papers, none met the final inclusion criterion of using PROMs proactively as a dialogue tool for ovarian cancer patients during follow-up.

Conclusion

Studies have shown that PROMs can identify otherwise undetected symptoms. Using PROMs proactively during the consultation has been shown to improve symptom management for patients with some other types of cancer. However, we found no studies that had examined the proactive use of PROMs during follow-up of ovarian cancer patients. Future studies should evaluate if the proactive use of PROMs could facilitate a more individualized and more effective follow-up program tailored to the ovarian cancer patient’s needs and preferences.
Appendix
Available only for authorised users
Literature
1.
go back to reference International Agency for Research on Cancer. Global cancer statistics 2012. . Accessed. International Agency for Research on Cancer. Global cancer statistics 2012. . Accessed.
2.
go back to reference Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet (London, England). 2010;376(9747):1155–63.CrossRef Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet (London, England). 2010;376(9747):1155–63.CrossRef
3.
go back to reference Dahl L, Wittrup I, Vaeggemose U, Petersen LK, Blaakaer J. Life after gynecologic cancer--a review of patients quality of life, needs, and preferences in regard to follow-up. Int J Gynecol Cancer. 2013;23(2):227–34.PubMedCrossRef Dahl L, Wittrup I, Vaeggemose U, Petersen LK, Blaakaer J. Life after gynecologic cancer--a review of patients quality of life, needs, and preferences in regard to follow-up. Int J Gynecol Cancer. 2013;23(2):227–34.PubMedCrossRef
4.
go back to reference Olesen ML, Hansson H, Ottesen B, Thranov IR, Thisted LB, Zoffmann V. The psychosocial needs of gynaecological cancer survivors: A framework for the development of a complex intervention. Eur J Oncol Nurs. 2015;19(4):349–58.PubMedCrossRef Olesen ML, Hansson H, Ottesen B, Thranov IR, Thisted LB, Zoffmann V. The psychosocial needs of gynaecological cancer survivors: A framework for the development of a complex intervention. Eur J Oncol Nurs. 2015;19(4):349–58.PubMedCrossRef
5.
go back to reference FDA. Guidance for Industry Patient-Reported Outcome Measures. Use in medical product development to support labeling claims. Clin FED Regist. 2009;2009:1–39. FDA. Guidance for Industry Patient-Reported Outcome Measures. Use in medical product development to support labeling claims. Clin FED Regist. 2009;2009:1–39.
6.
go back to reference Coulter A PC, Peters M, Fitzpatrick R. Cancer PROMs: a scoping study. Macmillan Cancer Support; 2015. Coulter A PC, Peters M, Fitzpatrick R. Cancer PROMs: a scoping study. Macmillan Cancer Support; 2015.
7.
go back to reference Lockwood-Rayermann S. Survivorship issues in ovarian cancer: a review. Oncol Nurs Forum. 2006;33(3):553–62.PubMedCrossRef Lockwood-Rayermann S. Survivorship issues in ovarian cancer: a review. Oncol Nurs Forum. 2006;33(3):553–62.PubMedCrossRef
8.
go back to reference Berry DL, Blumenstein BA, Halpenny B, et al. Enhancing patient-provider communication with the electronic self-report assessment for cancer: a randomized trial. J Clin Oncol. 2011;29(8):1029–35.PubMedPubMedCentralCrossRef Berry DL, Blumenstein BA, Halpenny B, et al. Enhancing patient-provider communication with the electronic self-report assessment for cancer: a randomized trial. J Clin Oncol. 2011;29(8):1029–35.PubMedPubMedCentralCrossRef
9.
go back to reference Sepucha KR, Levin CA, Uzogara EE, Barry MJ, O'Connor AM, Mulley AG. Developing instruments to measure the quality of decisions: early results for a set of symptom-driven decisions. Patient Educ Couns. 2008;73(3):504–10.PubMedCrossRef Sepucha KR, Levin CA, Uzogara EE, Barry MJ, O'Connor AM, Mulley AG. Developing instruments to measure the quality of decisions: early results for a set of symptom-driven decisions. Patient Educ Couns. 2008;73(3):504–10.PubMedCrossRef
10.
go back to reference Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22(4):714–24.PubMedCrossRef Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22(4):714–24.PubMedCrossRef
11.
go back to reference Hess LMP, Stehman FBMD. State of the science in ovarian Cancer quality of life research: A systematic review. Int J Gynecol Cancer. 2012;22(7):1273–80.PubMedCrossRef Hess LMP, Stehman FBMD. State of the science in ovarian Cancer quality of life research: A systematic review. Int J Gynecol Cancer. 2012;22(7):1273–80.PubMedCrossRef
12.
go back to reference Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine Cancer treatment. Jama. 2017;318(2):197–8.PubMedPubMedCentralCrossRef Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine Cancer treatment. Jama. 2017;318(2):197–8.PubMedPubMedCentralCrossRef
13.
go back to reference Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.PubMedCrossRef Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.PubMedCrossRef
14.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12.PubMedCrossRef Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12.PubMedCrossRef
15.
go back to reference Hess LM, Stehman FB. State of the science in ovarian cancer quality of life research: a systematic review. Int J Gynecol Cancer. 2012;22(7):1273–80.PubMedCrossRef Hess LM, Stehman FB. State of the science in ovarian cancer quality of life research: a systematic review. Int J Gynecol Cancer. 2012;22(7):1273–80.PubMedCrossRef
16.
go back to reference Hilpert F, Du Bois A. Patient-reported outcomes in ovarian cancer: are they key factors for decision making? Expert Rev Anticancer Ther. 2018;18(sup1):3–7.PubMedCrossRef Hilpert F, Du Bois A. Patient-reported outcomes in ovarian cancer: are they key factors for decision making? Expert Rev Anticancer Ther. 2018;18(sup1):3–7.PubMedCrossRef
17.
go back to reference Wiering B, de Boer D, Delnoij D. Patient involvement in the development of patient-reported outcome measures: a scoping review. Health Expect. 2017;20(1):11–23.PubMedCrossRef Wiering B, de Boer D, Delnoij D. Patient involvement in the development of patient-reported outcome measures: a scoping review. Health Expect. 2017;20(1):11–23.PubMedCrossRef
18.
go back to reference Preston NJ, Wilson N, Wood NJ, Brine J, Ferreira J, Brearley SG. Patient-reported outcome measures for use in gynaecological oncology: a systematic review. BJOG. 2015;122(5):615–22.PubMedCrossRef Preston NJ, Wilson N, Wood NJ, Brine J, Ferreira J, Brearley SG. Patient-reported outcome measures for use in gynaecological oncology: a systematic review. BJOG. 2015;122(5):615–22.PubMedCrossRef
19.
go back to reference Clarke T, Galaal K, Bryant A, Naik R. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database Syst Rev. 2014;(9). Clarke T, Galaal K, Bryant A, Naik R. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database Syst Rev. 2014;(9).
20.
go back to reference Kew F, Galaal K, Bryant A, Naik R. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. The Cochrane database of systematic reviews. 2011;(6):Cd006119. Kew F, Galaal K, Bryant A, Naik R. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. The Cochrane database of systematic reviews. 2011;(6):Cd006119.
21.
go back to reference Zikos E, Coens C, Quinten C, et al. The added value of analyzing pooled health-related quality of life data: A review of the EORTC PROBE initiative. J Natl Cancer Inst. 2016;108(5).PubMedCrossRef Zikos E, Coens C, Quinten C, et al. The added value of analyzing pooled health-related quality of life data: A review of the EORTC PROBE initiative. J Natl Cancer Inst. 2016;108(5).PubMedCrossRef
22.
go back to reference Ahmed-Lecheheb D, Joly F. Ovarian cancer survivors' quality of life: a systematic review. J Cancer Surviv. 2016;10(5):789–801.PubMedCrossRef Ahmed-Lecheheb D, Joly F. Ovarian cancer survivors' quality of life: a systematic review. J Cancer Surviv. 2016;10(5):789–801.PubMedCrossRef
23.
go back to reference Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. Jama. 2002;288(23):3027–34.PubMedCrossRef Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. Jama. 2002;288(23):3027–34.PubMedCrossRef
24.
go back to reference King MT, Stockler MR, O'Connell RL, et al. Measuring what matters MOST: validation of the measure of ovarian symptoms and treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation. 2018;27(1):59–74.CrossRef King MT, Stockler MR, O'Connell RL, et al. Measuring what matters MOST: validation of the measure of ovarian symptoms and treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation. 2018;27(1):59–74.CrossRef
25.
26.
go back to reference Meraner V, Gamper EM, Grahmann A, et al. Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy. BMC Cancer. 2012;12:77.PubMedPubMedCentralCrossRef Meraner V, Gamper EM, Grahmann A, et al. Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy. BMC Cancer. 2012;12:77.PubMedPubMedCentralCrossRef
27.
go back to reference Beesley VL, Price MA, Webb PM, et al. Changes in supportive care needs after first-line treatment for ovarian cancer: identifying care priorities and risk factors for future unmet needs. Psycho-oncology. 2013;22(7):1565–71.PubMedCrossRef Beesley VL, Price MA, Webb PM, et al. Changes in supportive care needs after first-line treatment for ovarian cancer: identifying care priorities and risk factors for future unmet needs. Psycho-oncology. 2013;22(7):1565–71.PubMedCrossRef
28.
go back to reference Stewart DE, Wong F, Duff S, Melancon CH, Cheung AM. "what doesn't kill you makes you stronger": an ovarian cancer survivor survey. Gynecol Oncol. 2001;83(3):537–42.PubMedCrossRef Stewart DE, Wong F, Duff S, Melancon CH, Cheung AM. "what doesn't kill you makes you stronger": an ovarian cancer survivor survey. Gynecol Oncol. 2001;83(3):537–42.PubMedCrossRef
29.
go back to reference Bodurka-Bevers D, Basen-Engquist K, Carmack CL, et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol. 2000;78(3 Pt 1):302–8.PubMedCrossRef Bodurka-Bevers D, Basen-Engquist K, Carmack CL, et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol. 2000;78(3 Pt 1):302–8.PubMedCrossRef
30.
go back to reference Greimel ER, Bjelic-Radisic V, Pfisterer J, et al. Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support Care Cancer. 2011;19(9):1421–7.PubMedCrossRef Greimel ER, Bjelic-Radisic V, Pfisterer J, et al. Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support Care Cancer. 2011;19(9):1421–7.PubMedCrossRef
31.
go back to reference Liavaag AH, Dorum A, Fossa SD, Trope C, Dahl AA. Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? J Clin Oncol. 2007;25(15):2049–56.PubMedCrossRef Liavaag AH, Dorum A, Fossa SD, Trope C, Dahl AA. Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? J Clin Oncol. 2007;25(15):2049–56.PubMedCrossRef
32.
go back to reference Matei D, Miller AM, Monahan P, et al. Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a gynecologic oncology group study. J Clin Oncol. 2009;27(25):4142–9.PubMedPubMedCentralCrossRef Matei D, Miller AM, Monahan P, et al. Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a gynecologic oncology group study. J Clin Oncol. 2009;27(25):4142–9.PubMedPubMedCentralCrossRef
33.
go back to reference Mercieca-Bebber RL, Price MA, Bell ML, King MT, Webb PM, Butow PN. Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time. Asia Pac J Clin Oncol. 2017;13(5):e381–8.PubMedCrossRef Mercieca-Bebber RL, Price MA, Bell ML, King MT, Webb PM, Butow PN. Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time. Asia Pac J Clin Oncol. 2017;13(5):e381–8.PubMedCrossRef
35.
go back to reference Chase DM, Wenzel L. Health-related quality of life in ovarian cancer patients and its impact on clinical management. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):421–31.PubMedPubMedCentralCrossRef Chase DM, Wenzel L. Health-related quality of life in ovarian cancer patients and its impact on clinical management. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):421–31.PubMedPubMedCentralCrossRef
36.
go back to reference Williams LA, Agarwal S, Bodurka DC, Saleeba AK, Sun CC, Cleeland CS. Capturing the patient's experience: using qualitative methods to develop a measure of patient-reported symptom burden: an example from ovarian cancer. J Pain Symptom Manag. 2013;46(6):837–45.CrossRef Williams LA, Agarwal S, Bodurka DC, Saleeba AK, Sun CC, Cleeland CS. Capturing the patient's experience: using qualitative methods to develop a measure of patient-reported symptom burden: an example from ovarian cancer. J Pain Symptom Manag. 2013;46(6):837–45.CrossRef
37.
go back to reference Greimel E, Bottomley A, Cull A, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer. 2003;39(10):1402–8.PubMedCrossRef Greimel E, Bottomley A, Cull A, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer. 2003;39(10):1402–8.PubMedCrossRef
38.
go back to reference Snyder CF, Aaronson NK. Use of patient-reported outcomes in clinical practice. Lancet (London, England). 2009;374(9687):369–70.CrossRef Snyder CF, Aaronson NK. Use of patient-reported outcomes in clinical practice. Lancet (London, England). 2009;374(9687):369–70.CrossRef
39.
go back to reference Bordlein-Wahl I, Hilpert F, Kohlmann T. Evaluating treatment from the point of view of the patient -PROs (patient-reported outcomes). Onkologie. 2009;32(Suppl 1):18–20.PubMedCrossRef Bordlein-Wahl I, Hilpert F, Kohlmann T. Evaluating treatment from the point of view of the patient -PROs (patient-reported outcomes). Onkologie. 2009;32(Suppl 1):18–20.PubMedCrossRef
40.
go back to reference Roncolato FT, Gibbs E, Lee CK, et al. Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy. Ann Oncol. 2017;28(8):1849–55.PubMedPubMedCentralCrossRef Roncolato FT, Gibbs E, Lee CK, et al. Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy. Ann Oncol. 2017;28(8):1849–55.PubMedPubMedCentralCrossRef
41.
go back to reference Jensen RE, Snyder CF. PRO-cision medicine: personalizing patient care using patient-reported outcomes. J Clin Oncol. 2016;34(6):527–9.PubMedCrossRef Jensen RE, Snyder CF. PRO-cision medicine: personalizing patient care using patient-reported outcomes. J Clin Oncol. 2016;34(6):527–9.PubMedCrossRef
42.
go back to reference Beesley VL, Smith DD, Nagle CM, et al. Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. Support Care Cancer. 2018;26(12):4133–42.PubMedCrossRef Beesley VL, Smith DD, Nagle CM, et al. Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. Support Care Cancer. 2018;26(12):4133–42.PubMedCrossRef
43.
go back to reference Du Bois A, Rochon J, Lamparter C, Pfisterer J. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer. 2005;15(2):183–91.PubMedCrossRef Du Bois A, Rochon J, Lamparter C, Pfisterer J. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer. 2005;15(2):183–91.PubMedCrossRef
44.
go back to reference Madalinska JB, van Beurden M, Bleiker EM, et al. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. J Clin Oncol. 2007;25(3):301–7.PubMedCrossRef Madalinska JB, van Beurden M, Bleiker EM, et al. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. J Clin Oncol. 2007;25(3):301–7.PubMedCrossRef
45.
go back to reference de Rooij BH, Ezendam NPM, Nicolaije KAH, et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2-year follow-up - the ROGY care trial. Gynecol Oncol. 2017;145(2):319–28.PubMedCrossRef de Rooij BH, Ezendam NPM, Nicolaije KAH, et al. Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2-year follow-up - the ROGY care trial. Gynecol Oncol. 2017;145(2):319–28.PubMedCrossRef
46.
47.
go back to reference Cesario SK, Nelson LS, Broxson A, Cesario AL. Sword of Damocles cutting through the life stages of women with ovarian cancer. Oncol Nurs Forum. 2010;37(5):609–17.PubMedCrossRef Cesario SK, Nelson LS, Broxson A, Cesario AL. Sword of Damocles cutting through the life stages of women with ovarian cancer. Oncol Nurs Forum. 2010;37(5):609–17.PubMedCrossRef
48.
go back to reference Keim-Malpass J, Mihalko SL, Russell G, Case D, Miller B, Avis NE. Problems experienced by ovarian Cancer survivors during treatment. J Obstet Gynecol Neonatal Nurs. 2017;46(4):544–54.PubMedPubMedCentralCrossRef Keim-Malpass J, Mihalko SL, Russell G, Case D, Miller B, Avis NE. Problems experienced by ovarian Cancer survivors during treatment. J Obstet Gynecol Neonatal Nurs. 2017;46(4):544–54.PubMedPubMedCentralCrossRef
49.
go back to reference Oberguggenberger A, Sztankay M, Morscher RJ, et al. Psychosocial outcomes and counselee satisfaction following genetic counseling for hereditary breast and ovarian cancer: A patient-reported outcome study. J Psychosom Res. 2016;89:39–45.PubMedCrossRef Oberguggenberger A, Sztankay M, Morscher RJ, et al. Psychosocial outcomes and counselee satisfaction following genetic counseling for hereditary breast and ovarian cancer: A patient-reported outcome study. J Psychosom Res. 2016;89:39–45.PubMedCrossRef
50.
go back to reference Stukenborg GJ, Blackhall LJ, Harrison JH, Dillon PM, Read PW. Longitudinal patterns of cancer patient reported outcomes in end of life care predict survival. Support Care Cancer. 2016;24(5):2217–24.PubMedCrossRef Stukenborg GJ, Blackhall LJ, Harrison JH, Dillon PM, Read PW. Longitudinal patterns of cancer patient reported outcomes in end of life care predict survival. Support Care Cancer. 2016;24(5):2217–24.PubMedCrossRef
51.
go back to reference Rietveld M, Husson O, Vos C, Van De Poll-Franse L, Ottevanger N. Perceived information provision, is it related to supportive care needs? Int J Gynecol Cancer. 2016;26 (Supplement 3:810.CrossRef Rietveld M, Husson O, Vos C, Van De Poll-Franse L, Ottevanger N. Perceived information provision, is it related to supportive care needs? Int J Gynecol Cancer. 2016;26 (Supplement 3:810.CrossRef
52.
go back to reference Beesley VL, Price MA, Butow PN, Green AC, Olsen CM, Webb PM. Physical activity in women with ovarian cancer and its association with decreased distress and improved quality of life. Psycho-oncology. 2011;20(11):1161–9.PubMedCrossRef Beesley VL, Price MA, Butow PN, Green AC, Olsen CM, Webb PM. Physical activity in women with ovarian cancer and its association with decreased distress and improved quality of life. Psycho-oncology. 2011;20(11):1161–9.PubMedCrossRef
53.
go back to reference Greimel E, Bjelic-Radisic V, Nagele E, Bliem B, Tamussino K. Quality of life in patients with ovarian cancer. [German]. Onkologe. 2019;25(2):151–6.CrossRef Greimel E, Bjelic-Radisic V, Nagele E, Bliem B, Tamussino K. Quality of life in patients with ovarian cancer. [German]. Onkologe. 2019;25(2):151–6.CrossRef
54.
go back to reference Pearman TP, Beaumont JL, Mroczek D, O'Connor M, Cella D. Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy. Cancer. 2018;124(5):991–7.PubMedCrossRef Pearman TP, Beaumont JL, Mroczek D, O'Connor M, Cella D. Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy. Cancer. 2018;124(5):991–7.PubMedCrossRef
55.
go back to reference Astrup GL, Hofso K, Bjordal K, et al. Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence. Acta Oncol. 2017;56(3):462–70.PubMedCrossRef Astrup GL, Hofso K, Bjordal K, et al. Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence. Acta Oncol. 2017;56(3):462–70.PubMedCrossRef
56.
go back to reference Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine Cancer treatment: A randomized controlled trial. J Clin Oncol. 2016;34(6):557–65.PubMedCrossRef Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine Cancer treatment: A randomized controlled trial. J Clin Oncol. 2016;34(6):557–65.PubMedCrossRef
57.
go back to reference Anderson RT, Peres LC, Camacho F, et al. Individual, social, and societal correlates of health-related quality of life among African American survivors of ovarian cancer: results from the African American cancer epidemiology study. J Women's Health. 2019;28(2):284–93.CrossRef Anderson RT, Peres LC, Camacho F, et al. Individual, social, and societal correlates of health-related quality of life among African American survivors of ovarian cancer: results from the African American cancer epidemiology study. J Women's Health. 2019;28(2):284–93.CrossRef
58.
go back to reference Hilarius DL, Kloeg PH, Gundy CM, Aaronson NK. Use of health-related quality-of-life assessments in daily clinical oncology nursing practice: a community hospital-based intervention study. Cancer. 2008;113(3):628–37.PubMedCrossRef Hilarius DL, Kloeg PH, Gundy CM, Aaronson NK. Use of health-related quality-of-life assessments in daily clinical oncology nursing practice: a community hospital-based intervention study. Cancer. 2008;113(3):628–37.PubMedCrossRef
59.
go back to reference Shalowitz DI, Schorge JO. Suggestibility of Oncologists' clinical estimates. JAMA oncology. 2015;1(2):251–3.PubMedCrossRef Shalowitz DI, Schorge JO. Suggestibility of Oncologists' clinical estimates. JAMA oncology. 2015;1(2):251–3.PubMedCrossRef
60.
go back to reference Kew FM, Cruickshank DJ. Routine follow-up after treatment for a gynecological cancer: a survey of practice. Int J Gynecol Cancer. 2006;16(1):380–4.PubMedCrossRef Kew FM, Cruickshank DJ. Routine follow-up after treatment for a gynecological cancer: a survey of practice. Int J Gynecol Cancer. 2006;16(1):380–4.PubMedCrossRef
61.
go back to reference Basch E, Artz D, Dulko D, et al. Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol. 2005;23(15):3552–61.PubMedCrossRef Basch E, Artz D, Dulko D, et al. Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol. 2005;23(15):3552–61.PubMedCrossRef
62.
go back to reference Hansen DG, Larsen PV, Holm LV, Rottmann N, Bergholdt SH, Sondergaard J. Association between unmet needs and quality of life of cancer patients: a population-based study. Acta Oncol. 2013;52(2):391–9.PubMedCrossRef Hansen DG, Larsen PV, Holm LV, Rottmann N, Bergholdt SH, Sondergaard J. Association between unmet needs and quality of life of cancer patients: a population-based study. Acta Oncol. 2013;52(2):391–9.PubMedCrossRef
63.
go back to reference Ploos van Amstel FKRNM, van Ham MAPCPMD, Peters EJM, Prins JBPM, Ottevanger PBPMD. Self-reported distress in patients with ovarian Cancer: is it related to disease status? Int J Gynecol Cancer. 2015;25(2):229–35.PubMedCrossRef Ploos van Amstel FKRNM, van Ham MAPCPMD, Peters EJM, Prins JBPM, Ottevanger PBPMD. Self-reported distress in patients with ovarian Cancer: is it related to disease status? Int J Gynecol Cancer. 2015;25(2):229–35.PubMedCrossRef
64.
go back to reference Howell D, Molloy S, Wilkinson K, et al. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol. 2015;26(9):1846–58.PubMedCrossRef Howell D, Molloy S, Wilkinson K, et al. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol. 2015;26(9):1846–58.PubMedCrossRef
Metadata
Title
Proactive use of PROMs in ovarian cancer survivors: a systematic review
Authors
Anette Stolberg Kargo
Angela Coulter
Pernille Tine Jensen
Karina Dahl Steffensen
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2019
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-019-0538-9

Other articles of this Issue 1/2019

Journal of Ovarian Research 1/2019 Go to the issue